ClinicalTrials.gg
CompletedNCT02529956Updated Aug 20, 2015

A Study to Assess the Safety, Pharmacokinetics and Pharmacodynamics of UCB4940 in Patients With Psoriasis

A Phase 1 interventional study of UCB4940 and Placebo in Mild to Moderate Psoriasis, sponsored by UCB Celltech. Completed at 1 site in United Kingdom. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2015-08-20.

Sponsored by UCB Celltech (part of UCB S.A.) · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
39
Allocation
Randomized
Ages
18 Years to 70 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 20 studies testing bimekizumab in Psoriasis — 4 open to participants now, 5 under way, 3 of them phase 3. bimekizumab · Psoriasis.

Enrollment
19th of 20
39 · median 161
Started
2012
the only one that year
Phase 1
Only one
of the 20
Registered
1st of 20
by date
Lead sponsor
1 of 20
UCB Celltech

Among the 20 studies testing bimekizumab in Psoriasis, this one is the 19th largest by enrollment, is the only one that started in 2012, is the only one in phase 1, and was the 1st registered.

Psoriasis

2,030 studies on the registry are indexed under Psoriasis; 276 are open to participants now.

Browse Psoriasis studies →

Open to participants now

4 of the 20 studies testing bimekizumab in Psoriasis are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

About bimekizumab

bimekizumab: first FDA approval 2023 (BIMZELX), first EMA approval 2021. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 173 Psoriasis studies recruiting now, 91 (53%) set no upper age limit and 66 (38%) stop at 75 or younger; 25 take children under 18; 40 take healthy volunteers.

This study: 18 Years to 70 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 20 studies testing bimekizumab in Psoriasis, or all of them as a file.
02

Study summary

To evaluate the safety of UCB4940 administered by iv infusion of a single ascending dose in subjects with mild to moderate plaque psoriasis.

03

Conditions studied

  • Mild to Moderate Psoriasis

Browse trials for

Keywords

  • Psoriasis
  • UCB4940
04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Subject is male or female, aged ≥ 18 years to ≤ 70 years at Screening. Female subjects must either be (at least 1 year), permanently sterilized or, if of , must be willing to use at least 2 effective methods of , including a barrier method during the study period. Effective methods of contraception are methods of birth control, which result in a low failure rate when used consistently and correctly, such as implants, injectables, oral contraceptives, progesterone-releasing intrauterine systems or the TCu 380A intrauterine device, complete sexual abstinence, or vasectomized partner. Male subjects with partners of childbearing potential must be willing to use a condom when sexually active. Both male and female subjects must use the above mentioned contraception for 20 weeks after administration of study drug (anticipated 5 half-lives)
  • Subject has had a confirmed diagnosis of mild to moderate plaque-type psoriasis for at least 6 months involving ≤ 5 % of body surface area (BSA) (excluding the scalp)
  • Subject has a of ≤ 35 kg/m\^2 at Screening
  • Subject has a minimum of 2 psoriatic lesions with at least 1 plaque in a site suitable for

Exclusion criteria

Exclusion Criteria:

  • Female subject who is pregnant, or plans to become pregnant during the study, or lactating, or sexually active with who is not using a medically accepted method
  • Subject has received systemic nonbiologic psoriasis therapy (methotrexate [MTX], , cyclophosphamide) or psoralen plus ultraviolet A (PUVA)/ultraviolet A (UVA) phototherapy within 4 weeks prior to Screening
  • Subject has received treatment with biologic agents within 12 months prior to the study
  • Subject has received within 6 weeks prior to Screening or intends to have such a vaccination during the course of the study
  • Subject has received any drug or experimental procedure within 90 days or 5 half-lives, whichever is longer, prior to IMP administration
  • Subject requires treatment with a nonsteroidal anti-inflammatory drug during the study period. Paracetamol will be permitted for use as an antipyretic and/or analgesic
  • Subject has an active infection (eg, sepsis, pneumonia, abscess) or has had a serious infection (resulting in hospitalization or requiring parenteral antibiotic treatment) within 6 weeks prior to IMP administration. When in doubt, the Investigator should confer with the UCB Study Physician
  • Subject has a history of a positive tuberculosis (TB) test or evidence of possible TB or latent TB infection at Screening that cannot be attributed to a prior Bacillus Calmette-Guérin inoculation
  • Subject has renal or liver impairment, defined as:

    • For women, serum creatinine level ≥ 125 μmol/L; for men, ≥ 135 μmol/L, or
    • and aspartate aminotransferase ≥ 2x , or
    • Alkaline phosphatase and > 1.5x ULN (an isolated bilirubin > 1.5x ULN is acceptable if bilirubin is fractionated and direct bilirubin is \< 35 %)
  • Subject has active neoplastic disease or history of neoplastic disease within 5 years of Screening (except for basal or squamous cell carcinoma of the skin or carcinoma in situ that has been definitively treated with standard of care)
Terms in these criteria, in plain language(11)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
39 participants (actual)

Study arms

  • Experimental
    UCB4940 8 mg

    Single intravenous (iv) infusion of UCB4940 8 mg over at least 60 minutes.

    Drug: UCB4940

  • Experimental
    UCB4940 40 mg

    Single intravenous (iv) infusion of UCB4940 40 mg over at least 60 minutes.

    Drug: UCB4940

  • Experimental
    UCB4940 160 mg

    Single intravenous (iv) infusion of UCB4940 160 mg over at least 60 minutes.

    Drug: UCB4940

  • Experimental
    UCB4940 480 mg

    Single intravenous (iv) infusion of UCB4940 480 mg over at least 60 minutes.

    Drug: UCB4940

  • Experimental
    UCB4940 640 mg

    Single intravenous (iv) infusion of UCB4940 640 mg over at least 60 minutes.

    Drug: UCB4940

  • Placebo comparator
    Placebo

    Single intravenous (iv) infusion of Placebo over at least 60 minutes.

    Other: Placebo

Interventions

  • * Active Substance: UCB4940 * Pharmaceutical Form: Solution for infusion * Concentration: 80 mg/ml * Route of Administration: Intravenous use

  • OtherPlacebo

    * Active Substance: Placebo * Pharmaceutical Form: Solution for infusion * Concentration: 0.9 % sodium chloride aqueous solution * Route of Administration: Intravenous use

06

What researchers measure

Primary outcomes

  1. Number of subjects reporting at least 1 Treatment-Emergent Adverse Event (TEAE) during the Treatment Period (20 Weeks)

    Time frame: Baseline to 20 Weeks

  2. Number of subjects prematurely discontinuing due to a Treatment-Emergent Adverse Event (TEAE) during the Treatment Period (20 Weeks)

    Time frame: Baseline to 20 Weeks

  3. Number of subjects reporting at least 1 Serious Adverse Event (SAE) during the Treatment Period (20 Weeks)

    Time frame: Baseline to 20 Weeks

Secondary outcomes

  1. Maximum plasma concentration (Cmax)

    Time frame: Pharmacokinetic samples will be taken predose and 0-48 hr post-dose, 72 hr post-dose, 96 hr post-dose, Week-1 through Week-20

  2. Area under the plasma concentration-time curve from time 0 to infinity (AUC(0-inf))

    Time frame: Pharmacokinetic samples will be taken predose and 0-48 hr post-dose, 72 hr post-dose, 96 hr post-dose, Week-1 through Week-20

  3. Area under the plasma concentration-time curve from time 0 to the time of last quantifiable concentration (AUC(0-t))

    Time frame: Pharmacokinetic samples will be taken predose and 0-48 hr post-dose, 72 hr post-dose, 96 hr post-dose, Week-1 through Week-20

  4. Time to reach Cmax (Tmax)

    Time frame: Pharmacokinetic samples will be taken predose and 0-48 hr post-dose, 72 hr post-dose, 96 hr post-dose, Week-1 through Week-20

  5. Terminal elimination half-life (t1/2)

    Time frame: Pharmacokinetic samples will be taken predose and 0-48 hr post-dose, 72 hr post-dose, 96 hr post-dose, Week-1 through Week-20

  6. First order terminal elimination rate constant (λz)

    Time frame: Pharmacokinetic samples will be taken predose and 0-48 hr post-dose, 72 hr post-dose, 96 hr post-dose, Week-1 through Week-20

  7. Total body clearance (CL)

    Time frame: Pharmacokinetic samples will be taken predose and 0-48 hr post-dose, 72 hr post-dose, 96 hr post-dose, Week-1 through Week-20

  8. Volume of distribution in terminal phase (Vz)

    Time frame: Pharmacokinetic samples will be taken predose and 0-48 hr post-dose, 72 hr post-dose, 96 hr post-dose, Week-1 through Week-20

  9. Percentage Change from Baseline to Week 12 in the Lesion Severity Score (LSS)

    Time frame: Baseline to Week 12

  10. Percentage Change from Baseline to Week 12 in thickness of the plaque

    Time frame: Baseline to Week 12

  11. Percentage Change from Baseline to Week 12 in lesion area

    Time frame: Baseline to Week 12

  12. Percentage Change from Baseline to Week 12 in Psoriasis Area and Severity Index (PASI)

    Time frame: Baseline to Week 12

  13. Percentage Change from Baseline to Week 12 in Physician's Global Assessment (PGA)

    Time frame: Baseline to Week 12

07

Study locations

1 site
  • 1
    Harrow, United Kingdom
08

References and documents

Publications

  • Glatt S, Helmer E, Haier B, Strimenopoulou F, Price G, Vajjah P, Harari OA, Lambert J, Shaw S. First-in-human randomized study of bimekizumab, a humanized monoclonal antibody and selective dual inhibitor of IL-17A and IL-17F, in mild psoriasis. Br J Clin Pharmacol. 2017 May;83(5):991-1001. doi: 10.1111/bcp.13185. Epub 2017 Jan 10. PubMed 27859546 ↗
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Nov 2012, a primary completion of Jan 2014 and a completion of Jan 2014. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 19, 2015
First posted
Aug 20, 2015
Start
Nov 2012
Primary completionActual
Jan 2014
CompletionActual
Jan 2014
Last update
Aug 20, 2015
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 20, 2015, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02529956
Lead sponsor
UCB Celltech
Responsible party
Sponsor
First posted
Aug 20, 2015
Start date
Nov 2012
Primary completion
Jan 2014
Completion
Jan 2014
Last update
Aug 20, 2015

Study contacts

UCB Clinical Trial Call Center
study director · +1 877 8229493 (UCB)

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2015. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Bimekizumab

Start the discussion